Singapore markets closed

GILD Jun 2025 85.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.6000+0.4500 (+20.93%)
At close: 09:30AM EDT
Full screen
Previous close2.1500
Open2.9800
Bid2.2700
Ask3.2500
Strike85.00
Expiry date2025-06-20
Day's range2.6000 - 2.9800
Contract rangeN/A
Volume8
Open interest882
  • Yahoo Finance Video

    US indexes open mixed, pharmaceutical stocks climb: Morning Brief

    On today's episode of Morning Brief, hosts Brad Smith and Madison Mills analyze the market open and break down the biggest stories of the trading week. The major indexes (^DJI, ^IXIC, ^GSPC) opened mixed in Friday's session, with the Dow Jones Industrial Average leading gains early in the trading day. Nvidia's (NVDA) reign as the US's most valuable publicly traded company was brief. The semiconductor giant shed $118 billion in market capitalization, allowing Microsoft (MSFT) to reclaim the top spot. Moor Insights & Strategy founder, CEO, and chief analyst Patrick Moorhead emphasizes that Nvidia's continued dominance hinges on sustained enterprise demand for its offerings. If customers stop buying Nvidia's offerings, he warns, "then this whole gravy train comes to a screeching halt." Wells Fargo Investment Institute senior global market strategist Scott Wren notes that while the computer services and technology sectors are currently "very highly valued, very momentum driven," investors should consider trimming some of their gains in these areas and reallocating into sectors like industrials, energy, and healthcare. The pharmaceutical and biotech sectors are making major moves as Sarepta (SRPT) received expanded approval from the Food and Drug Administration for its muscular dystrophy drug, and Gilead (GILD) saw encouraging results from its twice-yearly shot to prevent HIV. Meanwhile, Oppenheimer has upgraded Nike (NKE) from Perform to Outperform and raised its price target from $110 to $120. Meta (META) also received a bullish call, as KeyBanc raised its price target from $475 to $540, citing sustained advertising momentum. Keybanc Managing Director Justin Patterson explains that Meta's ad revenue is "accelerating sequentially" despite intensifying competition, indicating that "demand for Meta's advertisements remains very high." This post was written by Melanie Riehl

  • Yahoo Finance Video

    Gilead sees encouraging results from shot to prevent HIV

    Gilead (GILD) has seen encouraging results from its twice-yearly shot to prevent HIV. Yahoo Finance's Anjalee Khemlani reports more on the drug and how HIV treatments continue to be the largest contributor to the biotech company's market capitalization. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl

  • Zacks

    Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection

    Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.